C12N 2760/18311
Metapneumovirus
Official title: Metapneumovirus, e.g. avian pneumovirus
C12N2760/18311 (Metapneumovirus) appears on 88 US grants and 149 published applications in this corpus.
Search patents in C12N- Granted patents
- 88
- Published applications
- 149
- Assignees
- 76
- Inventors
- 267
- Latest grant
- 14 Jul 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1989 | 1 | 0 |
| 1990 | 0 | 0 |
| 1991 | 1 | 0 |
| 1992 | 0 | 0 |
| 1993 | 0 | 0 |
| 1994 | 0 | 0 |
| 1995 | 0 | 0 |
| 1996 | 0 | 0 |
| 1997 | 1 | 0 |
| 1998 | 0 | 0 |
| 1999 | 0 | 0 |
| 2000 | 0 | 0 |
| 2001 | 1 | 0 |
| 2002 | 1 | 2 |
| 2003 | 2 | 5 |
| 2004 | 1 | 6 |
| 2005 | 1 | 5 |
| 2006 | 0 | 4 |
| 2007 | 0 | 2 |
| 2008 | 2 | 4 |
| 2009 | 2 | 8 |
| 2010 | 3 | 7 |
| 2011 | 2 | 3 |
| 2012 | 0 | 2 |
| 2013 | 2 | 2 |
| 2014 | 5 | 5 |
| 2015 | 1 | 3 |
| 2016 | 3 | 3 |
| 2017 | 7 | 4 |
| 2018 | 4 | 5 |
| 2019 | 5 | 6 |
| 2020 | 4 | 10 |
| 2021 | 6 | 5 |
| 2022 | 5 | 14 |
| 2023 | 4 | 7 |
| 2024 | 7 | 19 |
| 2025 | 12 | 14 |
| 2026 | 5 | 4 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
- C12N 2760/18334Use of virus or viral component as vaccineIndexing code83
- C12N 2760/18322New viral proteins or individual genes, new structural or functional aspects ofIndexing code38
- C12N 2760/18321Viruses as suchIndexing code23
- C12N 2760/18341Use of virus, viral particle or viral elements as a vectorIndexing code20
- C12N 2760/18361Methods of inactivation or attenuationIndexing code6
- C12N 2760/18371Demonstrated in vivo effectIndexing code4
- C12N 2760/18323Virus like particles [vlp]Indexing code3
- C12N 2760/18351Methods of production or purification of viral materialIndexing code3
All 12 subgroupsShow fewer
Recent patents
- Recombinant human metapneumovirus F proteins and their use14 Jul 2026US 12,679,870 B2The United States of America, as represented by the Secretary, Department of Health and Human Services
- Betacoronavirus mRNA vaccines19 May 2026US 12,629,412 B2ModernaTX, Inc.
- Betacoronavirus mRNA vaccines17 Feb 2026US 12,551,734 B2ModernaTX, Inc.
- Chimeric RSV and HMPV F proteins, immunogenic compositions, and methods of use10 Feb 2026US 12,544,436 B2Children's Healthcare of Atlanta, Inc.
- Betacoronavirus RNA vaccines13 Jan 2026US 12,521,577 B2ModernaTX, Inc.
- Avian metapneumovirus isolates and immunogenic compositions therefrom20 Aug 2026US 2026/0240983 A1Iowa State University Research Foundation, Inc.
- Betacoronavirus mrna vaccines23 Apr 2026US 2026/0108595 A1ModernaTX, Inc.
- Betacoronavirus mrna vaccines9 Apr 2026US 2026/0097110 A1ModernaTX, Inc.
- Immunogenic compositions and uses thereof22 Jan 2026US 2026/0021175 A1Pfizer Inc.
- Recombinant metapneumovirus f proteins and their use25 Dec 2025US 2025/0387464 A1Institute for Research in Biomedicine
Most cited
By later US patents
- Combination PIV3/hMPV RNA vaccines110US 10,064,934 B2ModernaTX, Inc. · 2018
- Metapneumovirus strains and their use in vaccine formulations and sequences74US 8,722,341 B2MedImmune Vaccines, Inc. · 2014
- Respiratory virus nucleic acid vaccines53US 11,103,578 B2ModernaTX, Inc. · 2021
- HMPV/hPIV3 mRNA vaccine composition47US 11,351,242 B1ModernaTX, Inc. · 2022
- Betacoronavirus mRNA vaccine46US 10,702,600 B1ModernaTX, Inc. · 2020